Methylenedioxyethylamphetamine

Methylenedioxyethylamphetamine (MDEA), also known as 3,4-methylenedioxy-N-ethylamphetamine, is a psychoactive drug of the phenethylamine and amphetamine chemical classes. It is known for its entactogenic effects, and is an analogue of MDMA (3,4-methylenedioxy-N-methylamphetamine), commonly known as ecstasy.

History

MDEA was first synthesized in the 1920s by Merck, a German pharmaceutical company. However, it did not gain popularity until the 1980s, when it was rediscovered by Alexander Shulgin, a renowned chemist and psychopharmacologist.

Pharmacology

MDEA acts primarily as a serotonin-norepinephrine-dopamine releasing agent (SNDRA). It increases the amount of these neurotransmitters in the brain by binding to and partially blocking their transporter proteins. This leads to increased neurotransmitter activity, which is thought to be responsible for the drug's psychological effects.

Effects

The effects of MDEA are similar to those of MDMA, but are generally less intense and last for a shorter period of time. Users often report feelings of euphoria, increased empathy, and enhanced sensory perception. However, MDEA also has potential negative effects, including anxiety, paranoia, and neurotoxicity.

Legal Status

MDEA is classified as a Schedule I drug under the Controlled Substances Act in the United States, meaning it is illegal to manufacture, distribute, or possess without a license. It is also controlled in many other countries under their respective drug laws.

See Also

• MDMA
• Amphetamine
• Psychoactive drug
• Controlled Substances Act

This pharmaceutical related article is a stub. You can help WikiMD by expanding it.